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In the present study, we assessed the incidence of adverse events and influenza-like symptoms in a working
population in Switzerland that was vaccinated against influenza. A total of 12,582 individuals of working age
(!65 years old) were offered a free influenza vaccine of their choice (injectable or intranasal vaccine) in October
and November 2000. Of these individuals, 1600 were vaccinated against influenza. Ninety-seven percent of
the vaccine recipients chose the intranasal vaccine, and 3% chose the injectable influenza vaccine. The incidence
of influenza-like symptoms and side effects was 13% and 36%, respectively. Individuals who chose the intranasal
vaccine were more likely to report side effects (OR, 3.23; 95% CI, 1.29–8.08). Facial paralysis was observed
in 11 patients and was the most severe adverse event associated with the intranasal influenza vaccine. As a
result of these adverse events, the intranasal vaccine was removed from the market in the fall of 2001.
Influenza infections are associated with substantial
morbidity and mortality and typically occur during the
winter months in the northern hemisphere [1–4]. The
incidence of influenza is usually highest among children
[5]. However, more than any other group, elderly in-
dividuals 165 years of age and individuals with under-
lying chronic disease conditions are at increased risk of
serious illness and death from influenza [2, 3, 6]. Vac-
cination is the primary measure to prevent ill health
associated with infection due to the influenza virus [7].
The Centers for Disease Control and Prevention (CDC;
Atlanta, GA) therefore recently recommended that per-
sons aged 65 years and adults and children with
chronic disorders of the pulmonary or cardiovascular
system or with chronic metabolic diseases such as di-
abetes mellitus should be vaccinated against influenza
[8]. In addition, the CDC recommended that persons
aged 50–64 years be vaccinated against influenza, be-
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cause the prevalence of high-risk conditions is high in
this age group [8].
However, influenza vaccination has hitherto been
available only as an injectable vaccine, which may be
an inconvenient route of administration for many in-
dividuals. Fear of injections and the inconvenience as-
sociated with them may prevent many potential can-
didates from receiving vaccination against influenza. A
novel intranasal influenza vaccine (Nasaflu [Berna Bio-
tech AG]) that is applied as a nasal spray was introduced
in Switzerland in October 2000 [9, 10]. This vaccine
was removed from the market in the fall of 2001 because
of a possible association with facial paralysis. It should
be noted that, in the meantime, another intranasal vac-
cine has been introduced on the market (FluMist;
MedImmune Vaccines). This second intranasal vaccine
is based on a live attenuated, cold-adapted influenza
virus, as opposed to the inactivated, virosome-formu-
lated subunit vaccine used in our study [11–13]. The
intranasal virosomal vaccine used in our study contains
as an adjuvant a heat-labile Escherichia coli toxin [9,
10]. The frequency and type of side effects are impor-
tant for determining the long-term acceptability of the
vaccine in the population. In the present study, we
therefore investigated the safety of the intranasal vi-
rosomal influenza vaccine in a working population. In
addition, we analyzed factors that are associated with
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developing side effects and influenza-like illness despite
vaccination.
PATIENTS AND METHODS
Patients. A total of 12,582 employees of the Canton Basel-
Stadt in Switzerland were offered the opportunity to receive
vaccination against influenza in October and November 2000,
before the epidemic period of 2000–2001. The Canton Basel-
Stadt is one of the 26 Cantons (states) in Switzerland, and its
official institutional bodies include several departments (such
as the Department for Social Support and the Department of
Education) in which employees of the Canton may work. In-
dividuals who were interested in being vaccinated against in-
fluenza were asked to complete an initial questionnaire with
information on their age, sex, history of allergy, pregnancy
status, and presence of a chronic disease. Additional data such
as household size and number of children were not obtained.
Also, we did not obtain data on those individuals who were
not interested in being vaccinated, because data collection
started with the first questionnaire. On return of the completed
first questionnaire, these individuals received a free receipt for
an influenza vaccine of their choice: either injectable vaccine
(e.g., Influvac [Solvay Pharma]) or intranasal spray (Nasaflu
[Berna Biotech]). The intranasal spray represented an inacti-
vated, virosome-formulated subunit vaccine. The components
of the vaccines for influenza vaccination corresponded to the
recommendations of the World Health Organization for the
influenza season of 2000–2001 and included the following
strains: A/Moscow/10/99 (H3N2)-like virus, A/New Caledonia/
20/99 (H1N1)-like virus, and B/Beijing/184/93-like virus (see
http://www.who.int; accessed 3 March 2004). The general rec-
ommendations for influenza vaccination in Switzerland are
available at http://www.bag.admin.ch/infekt/ (accessed 5 Jan-
uary 2003).
Individuals who chose the nasal spray received instructions
for the application of the vaccine in the respective pharmacies.
The spray was administered by the vaccine recipient, with 1
spray puff in each nostril, using an atomizer. The atomizer was
inserted as deeply as possible into the nostrils and then tilted
upwards to the horizontal position. The spray was then released
while pressing on the atomizer and breathing in through the
nose. The same procedure was used to administer the second
spray 1 week after administration of the first dose. Most of
those individuals who chose the injectable vaccine received the
injection at the Department of Public Health (Canton Basel-
Stadt).
In June 2001, all individuals who had filled in the first ques-
tionnaire were sent a second questionnaire. The second ques-
tionnaire included questions asking whether the vaccinated in-
dividuals experienced influenza-like symptoms, defined as a
temperature of 138C and 2 of the following symptoms:
cough, sore throat (pharyngitis), pain in the extremities (my-
algia), and headache [14]. In addition, the second questionnaire
elicited whether and what type of side effects were experienced
after vaccination. The first reports of facial paralyses following
intranasal vaccination were known at that time, and the second
questionnaire therefore specifically asked whether a facial pa-
ralysis had occurred. Individuals who indicated that they had
experienced serious side effects were contacted by telephone to
elicit further details about the case history. Moreover, the sec-
ond questionnaire elicited the type of vaccination chosen (in-
jectable or nasal spray), whether individuals were vaccinated
against influenza in the preceding winter of 1999–2000, and
whether individuals had experienced influenza-like symptoms
during the preceding winter.
Statistical analysis. Because the study population repre-
sents a closed cohort with a fixed follow-up period, the inci-
dence of influenza-like symptoms despite vaccination was cal-
culated as the proportion of individuals who experienced
influenza-like symptoms in the winter of 2000–2001. The in-
cidence of side effects following vaccination was calculated in
a similar fashion.
Factors associated with developing influenza-like symptoms
were first analyzed in an univariate binary logistic regression
model. This model included sex, age, type of vaccine (i.e., nasal
spray vs. injection), presence of a chronic disease, history of
allergy, side effects after vaccination, presence of influenza-like
symptoms in the winter of 1999–2000, and whether individuals
were vaccinated in the winter of 1999–2000. Factors with a P
value of !.1 were further analyzed in a multivariate binary
logistic regression model, adjusting for age and sex.
Factors associated with side effects following vaccination
were first analyzed in a univariate binary logistic regression
model. This model included sex, age, type of vaccine (nasal
spray vs. injection), history of allergy, presence of influenza-
like symptoms during the winter of 1999–2000, and whether
individuals were vaccinated during the winter of 1999–2000.
Factors with a P value of !.1 were further analyzed in a mul-
tivariate binary logistic regression model, adjusting for age
and sex.
The linearity assumption of the only continuous variable
(i.e., age) was checked using graphical tests and restricted cubic
spline functions [15]. Moreover, we checked for possible in-
teractions in the multivariate models. All statistical analyses
were conducted using the software package S-Plus, Professional
Edition, version 6.1 (Insightful).
RESULTS
Patients. A total of 1623 individuals out of 12,582 potential
candidates completed the first questionnaire and received a
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Figure 1. Flowchart indicating the number of individuals considered
for and included in an intranasal influenza vaccine study in Canton Basel-
Stadt, Switzerland.
prescription for a free influenza vaccine. Of these, 1600 decided
to receive vaccination. A total of 1526 individuals were followed
up for 1 year (i.e., completed the second questionnaire) (figure
1). Only 4.6% of those who received vaccination were lost to
follow-up. The characteristics of the 1526 individuals who com-
pleted the second questionnaire are shown in table 1. The ma-
jority of these individuals (72%) were male, and the mean age
was 45 years (range, 17–64 years). The vast majority (96.7%)
of subjects chose the nasal spray over the injection. There was
no specific algorithm for obtaining either vaccine, but the in-
jectable vaccine was mainly recommended for elderly people
and those with chronic diseases. In accordance with this rec-
ommendation, the proportion of individuals using the inject-
able influenza vaccine was greater among individuals with
chronic diseases than among those who did not have a chronic
disease (11% vs. 3%, respectively; ). However, the meanP ! .001
age of those individuals who chose the injection was not sig-
nificantly greater than that of those who chose the nasal spray
(47 years vs. 45 years, respectively; ). The reasons forPp .19
choosing the intranasal spray are shown in table 1. A total of
57 individuals only received 1 spray and indicated that they
did not use the second spray for the following reasons: side-
effects (28 individuals), forgetfulness (12) or other reasons (17).
Only 14% of subjects who chose the nasal spray indicated that
they had chosen it because of a fear of injections, whereas 47%
indicated other reasons for their choice (which were not further
detailed). Twenty-nine percent of all subjects indicated that they
had experienced influenza-like symptoms during the preceding
winter (1999–2000). Twelve percent of subjects indicated that
they were vaccinated against influenza during the preceding
winter (using the injectable vaccine, as the intranasal vaccine
was not available). Of these 12%, 156 (84%) chose the intran-
asal vaccine in 2000–2001.
Influenza-like symptoms. The incidence of influenza-like
symptoms despite vaccination in the study population was 13%
(198 of 1526). Factors associated with developing influenza-
like symptoms are shown in table 2. In a univariate analysis,
female subjects and younger subjects were more likely to de-
velop influenza-like symptoms than were other subjects. More-
over, subjects who had experienced adverse events and subjects
with a general history of allergy after vaccination were more
likely than other subjects to develop influenza-like symptoms.
Subjects who had experienced influenza-like symptoms in the
preceding year were also more likely than other subjects to
develop influenza-like symptoms. In a multivariate analysis,
accounting for the joint effect of the main predictors and ad-
justed for age and sex, only the presence of side effects after
vaccination and the history of influenza-like symptoms in the
preceding year were associated with an increased risk of de-
veloping influenza-like symptoms.
Side effects. The incidence of side effects following vac-
cination was 36% (545 of 1526 subjects) in the study popu-
lation. The side effects experienced by the vaccinated individ-
uals are shown in table 3. Individuals who received the nasal
spray could experience side effects twice, because the spray was
administered twice1 week apart. Sneezing and/or runny nose
were the most common side effects after vaccination, followed
by fatigue and arthralgia and/or myalgia.
Factors associated with developing side effects following vac-
cination are shown in table 4. In a univariate analysis, females
and younger individuals were more likely to report side effects.
Side effects were more frequent when the nasal spray was used,
as opposed to when the injectable vaccine was used (OR, 3.23;
95% CI, 1.29–8.08). Individuals with a general history of allergy
and individuals who had experienced influenza-like symptoms
during the preceding winter were more likely to report side
effects. Moreover, people vaccinated against influenza during
the preceding winter were less likely to report side effects. In
a multivariate analysis adjusted for age and sex, the direction
of the ORs remained the same, with statistical significance for
all independent variables other than having experienced influ-
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Table 1. Characteristics of 1526 subjects vaccinated against
influenza in Canton Basel-Stadt, Switzerland, winter 2000–2001.
Characteristic Value
Female sex 425 (28)
Age, mean years  SD 44.9  10.4
History of allergy 262 (17)
Presence of chronic disease 89 (6)
Developed influenza-like symptoms 198 (13)
No prior influenza vaccination 1137 (75)
Type of vaccinationa
Injection 49 (3.3)
Nasal spray 1429 (96.7)
Reason for choosing nasal sprayb
Fear of injection 203 (14)
Less-inconvenient side effects 234 (16)
Increased efficacy 325 (23)
Other 667 (47)
History of influenza-like symptoms during
winter 1999–2000 440 (29)
Vaccinated against influenza during
winter 1999–2000 186 (12)
NOTE. Data are no. (%) of subjects, unless otherwise indicated.
a Data are missing for 48 subjects.
b Data are for 1429 individuals who received nasal spray vaccination.
Table 2. Factors associated with developing influenza-like symptoms in
Canton Basel-Stadt, Switzerland, winter 2000–2001.
Analysis, risk factor OR (95% CI) P
Univariate analysis
Sex, female/male 1.50 (1.08–2.07) .015
Age, by decade 0.66 (0.57–0.76) !.001
Vaccination method, nasal spray/injection 0.52 (0.26–1.02) .058
Influenza-like symptoms in winter 1999–2000 2.72 (1.98–3.75) !.001
Vaccination against influenza in winter 1999–2000 0.78 (0.48–1.26) .312
Side effects after vaccination in 2000–2001 2.52 (1.82–3.45) !.001
Chronic disease 1.38 (0.77–2.47) .274
History of allergy 1.65 (1.15–2.36) .006
Multivariate analysis
Sex, female/male 1.02 (0.69–1.53) .896
Age, by decade 0.69 (0.58–0.83) !.001
Vaccination method, nasal spray/injection 0.52 (0.18–1.43) .203
Side effects after vaccination in 2000–2001 2.24 (1.54–3.26) !.001
History of allergy 1.28 (0.82–1.98) .274
Influenza-like symptoms in winter 1999–2000 2.22 (1.53–3.19) !.001
enza-like symptoms during the preceding winter (1999–2000)
(table 4).
The most severe side effect was facial paralysis. Four indi-
viduals experienced a facial paralysis after administration of the
first spray of the nasal influenza vaccine. After administration
of the second spray, there were 15 reported cases of facial pa-
ralysis. These cases included those of 3 of the 4 patients who
experienced a facial paralysis after administration of the first
nasal spray, resulting in a total of 12 patients who indicated
that they had developed a facial paralysis. The diagnoses were
based on patient history and clinical examinations. In 4 pa-
tients, a CT scan or MRI of the head was performed (none of
which revealed any pathological findings). In 1 patient, trigem-
inus neuropathia was the most likely diagnosis; however, the
facial nerve may have been affected as well. Therefore, there
were actually 11 patients (8 male and 3 female) who experienced
a unilateral facial paralysis after application of the nasal spray
vaccine. The facial paralysis was on the right side in 6 patients,
on the left side in 4 patients, and 1 patient could not indicate
exactly on which side of the face the paralysis was located. The
mean age (SD) of the patients was years (range, 24–41 14
69 years). The mean period between administration of the most
recent spray and the occurrence of a facial paralysis was 20
days (range, 3–43 days). The mean duration of the reversible
facial paralyses was 26 days (range, 1.5–60 days). Within the
study period, one 52-year-old patient indicated that the symp-
toms were not completely reversible. Because of a possible as-
sociation with facial paralysis, the nasal vaccine was removed
from the market in the fall of 2001.
DISCUSSION
In this study, we have shown that the majority (87%) of subjects
in the working population do not wish to be vaccinated against
influenza and that, among those who wish to be vaccinated,
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Table 3. Reported side effects in individuals who were vac-
cinated against influenza in Canton Basel-Stadt, Switzerland,
winter 2000–2001.
Side effect
No. of patients
reporting side effect
after vaccination,
by vaccination method
Injection
Nasal spray,
by dose
First Second
Sneezing and/or runny nose 8 428 388
Coughing 3 74 93
Arthralgia and/or myalgia 6 132 135
Malaise and diarrhea 2 36 29
Fatigue 5 143 134
Temperature of 138C 1 20 24
Herpes 1 16 17
Facial paralysisa … 4 11
Pain at the side of injection 3 … …
Skin irritation at the side of injection 3 … …
Other 1 88 99
NOTE. Multiple side effects per patient are possible; total number of
individuals with side effects is 545.
a Three patients with facial paralysis after the first spray also reported facial
paralysis after the second spray. In 1 patient, trigeminus neuropathia was the
most likely diagnosis; however, the facial nerve may also have been affected.
Therefore, there were a total of 11 patients who experienced a definite facial
paralysis after application of the nasal spray vaccine.
the nasal spray is the preferred route of administration for 97%.
We have also shown that side effects following vaccination oc-
curred in 36% of vaccine recipients, that side effects were more
frequent in subjects who received the intranasal spray, and that
the intranasal vaccine may be associated with a unilateral,
mostly reversible facial paralysis.
The majority of the working population does not wish to
be vaccinated against influenza, and among those who wish to
be vaccinated, the nasal spray is preferred. Only 1623 individ-
uals out of the 12,582 persons who were offered a free influenza
vaccine were interested in being vaccinated against influenza,
and 1600 (12.7%) actually received vaccination. This figure is
somewhat greater than the coverage rate of 8.2% in a French
working population reported by Millot et al. [16]. However,
among individuals at risk for serious illness for whom vacci-
nation has been recommended in recent guidelines, higher cov-
erage rates have been reported. For example, Kamal et al. [17]
reported an immunization rate of 66.7% among individuals
165 years of age, and in a similar study by Dannetun et al.
[18], a coverage rate of 30% in the same age group has been
estimated. The high coverage rate in our working population
may be due to the fact that a new intranasal influenza vaccine
was available, which is considered by most individuals to have
a more convenient route of administration than an injectable
vaccine. This argument is also in line with the fact that a striking
97% of our subjects preferred the intranasal vaccine, compared
with only 3% who chose the injectable vaccine. In our analysis,
experiencing side effects following vaccination and having in-
fluenza-like illness during the preceding influenza season were
associated with a greater risk of experiencing influenza-like
symptoms during the winter of 2000–2001. This suggests that
these individuals may be more susceptible to influenza infection
than other individuals despite having received vaccination. Al-
ternatively, one may speculate that the living conditions of these
individuals might be different from those of other subjects and
that those conditions put them at greater risk of influenza
infection.
Side effects following vaccination occurred in 36% of vaccine
recipients, side effects were more frequent among subjects who
received the intranasal spray, and the intranasal vaccine may
be associated with a unilateral reversible facial paralysis. The
side effects following vaccination have been reported previously
[9, 10]. In a previous study, the rate of adverse reactions fol-
lowing intranasal vaccination was ∼25%–30% [9]. This in-
cluded local and systemic responses such as runny nose, sneez-
ing, headache, malaise, and arthralgias [9]. The corresponding
figures in our study were similar, and the overall incidence of
side effects was 36%. However, in 11 patients who were vac-
cinated with the intranasal vaccine, a facial paralysis was re-
ported, and 1 case of trigeminus neuropathia was described.
This corresponds to an incidence of 0.7% (11 of 1526 subjects),
which is higher than the spontaneous incidence of 0.02%–
0.04% reported in the literature [19, 20]. The reversibility of
the facial paralysis was documented in all but 1 patient. Because
of a possible association with facial paralysis, the intranasal
influenza vaccine was removed from the market in the fall of
2001. It should be emphasized that this adverse event was not
known at the time that the intranasal vaccine was introduced.
Moreover, the time lag between administration of the intranasal
spray and the occurrence of a facial paralysis ranged from 3–
43 days, suggesting that further exploration is needed to de-
termine the nature of this possible association. It is also not
clear whether facial paralysis was the result of a local immune
reaction or was caused by the intranasal vaccine itself. One may
speculate that the adjuvant heat-labile toxin may have induced
these adverse events. It should be mentioned that these side
effects have not been reported in association with another in-
tranasal vaccine (FluMist [MedImmune Vaccines]) that is based
on a live attenuated, cold-adapted influenza virus. However,
this alternative intranasal vaccine is not recommended for
individuals of 150 years of age or for patients with chronic
conditions.
In our study, most side effects were mild, as indicated in
table 3. Nonetheless, individuals who chose the intranasal vac-
cine were more likely than others to develop side effects fol-
Intranasal Influenza Vaccine • CID 2004:38 (1 April) • 979
Table 4. Factors associated with developing side effects following vacci-
nation against influenza in Canton Basel-Stadt, Switzerland, winter 2000–2001.
Analysis, risk factor OR (95% CI) P
Univariate analysis
Sex, female/male 1.79 (1.41–2.29) !.001
Age, by decade 0.73 (0.66–0.81) !.001
Vaccination method, nasal spray/injection 2.28 (1.12–4.65) .024
Influenza-like symptoms in winter 1999–2000 1.28 (1.00–1.62) .046
Vaccination against influenza in winter 1999–2000 0.62 (0.44–0.88) .008
History of allergy 1.68 (1.26–2.23) !.001
Multivariate analysis
Sex, female/male 1.83 (1.39–2.42) !.001
Age, by decade 0.75 (0.66–0.85) !.001
Vaccination method, nasal spray/injection 3.23 (1.29–8.08) .012
Influenza-like symptoms in winter 1999–2000 1.18 (0.90–1.55) .221
Vaccination against influenza in winter 1999–2000 0.63 (0.43–0.93) .022
History of allergy 1.49 (1.07–2.06) .018
lowing vaccination (OR, 3.23; 95% CI, 1.29–8.08). This is not
surprising, because the intranasal spray causes a local reaction,
which is in line with our finding that runny nose and sneezing
were the most frequent transient adverse reactions. Females
were more likely than males to report side effects. In addition,
individuals with a known history of allergy and individuals who
were vaccinated against influenza during the preceding influ-
enza season were more likely than others to report side effects.
This suggests an altered immune response in these individuals
to the vaccine content.
Our study has several limitations. First, most individuals who
were offered a free vaccine decided not to receive vaccination.
The reason for this decision was not elicited, because only those
individuals who were interested in receiving vaccination ac-
tually completed the first questionnaire. It may well be that the
majority of the younger working population were aware of the
less-serious consequences of influenza in healthy adults and,
therefore, prefered not to receive vaccine. However, a more
comprehensive study would be needed to elicit the preferences
of those who did not wish to receive vaccination. Second, self-
selection of individuals into the 2 treatment groups may have
biased the estimate of the OR. Third, we used influenza-like
illness as the endpoint, and influenza infection was not virol-
ogically confirmed. However, virological influenza diagnostic
tests are not commonly performed in general practice, and
clinical diagnoses based on symptoms are more in line with a
real-world setting. Another limitation is that subjects may not
have recalled all symptoms when asked in June 2001 (i.e., there
may have been a recall bias). However, we believe that the
population was rather sensitized to vaccine-related side ef-
fects and to whether influenza-like symptoms occurred after
vaccination.
In conclusion, most working adults do not wish to be vac-
cinated against influenza. Among those who do wish to be
vaccinated, the intranasal spray was the most-frequently pre-
ferred route of administration. However, because of a possible
association with facial paralysis, the Swiss intranasal vaccine
was removed from the market in the fall of 2001. A recently
published study also suggests a strong association between this
inactivated intranasal influenza vaccine and Bell palsy [21].
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